RNAC
Cartesian Therapeutics Inc.
NASDAQ: RNAC · HEALTHCARE · BIOTECHNOLOGY
$6.22
-3.86% today
Updated 2026-04-30
Market cap
$199.26M
P/E ratio
—
P/S ratio
71.24x
EPS (TTM)
$-5.02
Dividend yield
—
52W range
$6 – $16
Volume
0.2M
Cartesian Therapeutics Inc. (RNAC) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-12.69M | $-22.46M | $-19.68M | $-52.04M | $-59.16M | $-51.44M | $34.88M | $-60.38M | $-31.63M | $-51.16M | $-23.67M | $-73.94M |
| Capital expenditures | $227000.00 | $1.16M | $586000.00 | $733000.00 | $884000.00 | $47000.00 | $815000.00 | $1.08M | $1.20M | $206000.00 | $9.09M | $5.45M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $1.22M | $1.13M | $2.05M | $4.08M | $5.71M | $5.16M | $5.42M | $7.72M | $11.19M | $22.52M | $6.58M | $10.52M |
| Free cash flow | $-12.91M | $-23.63M | $-20.27M | $-52.77M | $-60.05M | $-51.48M | $34.07M | $-61.47M | $-32.83M | $-51.37M | $-32.77M | $-79.39M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | $4.57M | $25.45M | — | $28000.00 | $184000.00 | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | $48.51M | $-24.63M | $-7.42M | — | — | — |